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  All	  platinum	  (Pt)-­‐based	  chemotherapeutics	  exert	  their	  efficacy	  primarily	  via	  the	   formation	  of	  DNA	  adducts	  which	   interfere	  with	  DNA	   replication,	   transcription	  and	  cell	  division	  and	  ultimately	   induce	  cell	  death.	   	  Repair	  and	  tolerance	  of	  Pt-­‐DNA	  lesions	   by	   nucleotide	   excision	   repair	   and	   homologous	   recombination	   (HR)	   can	  substantially	   reduce	   the	  effectiveness	  of	   the	  Pt	   therapy.	   	   Inhibition	  of	   these	  repair	  pathways,	  therefore,	  holds	  the	  potential	  to	  sensitize	  cancer	  cells	  to	  Pt	  treatment	  and	  increase	  clinical	  efficacy.	   	  Replication	  Protein	  A	  (RPA)	  plays	  essential	  roles	   in	  both	  NER	   and	  HR,	   along	  with	   its	   role	   in	   DNA	   replication	   and	   DNA	   damage	   checkpoint	  activation.	   	   Each	   of	   these	   functions	   requires	   RPA	   binding	   to	   single-­‐stranded	   DNA	  (ssDNA).	   We	   synthesized	   structural	   analogs	   of	   our	   previously	   reported	   RPA	  inhibitor	  TDRL-­‐505,	  determined	   the	   structure	  activity	   relationships	  and	  evaluated	  their	   efficacy	   in	   tissue	   culture	  models	  of	   epithelial	   ovarian	   cancer	   (EOC)	  and	  non-­‐small	  cell	  lung	  cancer	  (NSCLC).	  	  These	  data	  led	  us	  to	  the	  identification	  of	  TDRL-­‐551,	  which	  exhibited	  a	  greater	  than	  2-­‐fold	  increase	  in	  in	  vitro	  and	  cellular	  activity.	  	  TDRL-­‐551	  showed	  synergy	  with	  Pt	  in	  tissue	  culture	  models	  of	  EOC	  and	  in	  vivo	  efficacy,	  as	  a	  single	  agent	  and	  in	  combination	  with	  platinum,	  in	  a	  NSCLC	  xenograft	  model.	  	  These	  data	  demonstrate	  the	  utility	  of	  RPA	  inhibition	  in	  EOC	  and	  NSCLC	  and	  the	  potential	  in	  developing	  novel	  anticancer	  therapeutics	  that	  target	  RPA-­‐DNA	  interactions.	  	   John	  J.	  Turchi,	  Ph.D.,	  Chair	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1. INTRODUCTION	  1.1. Platinum	  based	  chemotherapy	  –	  a	  major	  landmark	  in	  the	  history	  of	  anticancer	  treatment	  regimens.	  	   Platinum	   (Pt)	   was	   the	   first	   metal	   to	   be	   established	   as	   a	   cancer	  chemotherapeutic	   (1).	   Cisplatin,	   the	   first	   Pt-­‐based	   drug	   continues	   to	   be	   the	  most	  commonly	   prescribed	   agent	   for	   cancer	   treatment	   half	   a	   century	   since	   the	  serendipitous	  discovery	  of	  its	  biological	  properties	  (2).	  	  The	  use	  of	  cisplatin	  has	  had	  a	  major	  impact	  especially	  in	  the	  treatment	  of	  solid	  malignancies	  such	  as	  testicular,	  ovarian	   and	   lung	   cancer.	   Particularly	   in	   the	   case	   of	   testicular	   cancer,	   platinum	   in	  combination	   with	   other	   chemotherapeutic	   agents	   –bleomycin	   and	   etoposide	  remarkably	  improved	  the	  survival	  rates	  in	  patients	  from	  5%	  to	  upto	  95%	  (3).	  This	  was	  a	  major	  landmark	  in	  the	  history	  of	  successful	  anticancer	  drugs.	  	  	   Although	  highly	  efficacious,	  some	  of	  the	  major	  concerns	  with	  cisplatin-­‐based	  therapy	  were	   its	   side	   effects	   particularly	   nephrotoxicity	   and	   neurotoxicity,	   which	  led	   to	   the	   development	   of	   its	   structural	   analogue	   carboplatin	   (4).	   Carboplatin	   has	  similar	  efficacy	  to	  cisplatin	  with	  reduced	  side	  effects.	  The	  mechanism	  of	  action	   for	  cisplatin	  and	  carboplatin	  involves	  coordinate	  covalent	  binding	  to	  the	  purine	  bases	  of	  DNA	  (4).	  Cisplatin	  (chemical	  formula:	  cis-­‐[Pt(Cl)2(NH3)2](II))	  (becomes	  activated	  by	  an	  intra-­‐cellular	  process	  of	  aquation	  and	  displacement	  of	  one	  of	  its	  chloride	  leaving	  groups.	  This	  form	  of	  cisplatin	  actively	  reacts	  to	  one	  of	  the	  purine	  bases,	  preferably	  guanine	   and	   forms	   a	   coordinate	   covalent	   bond.	   Subsequently,	   the	   other	   chloride	  group	  in	  cisplatin	  also	  gets	  displaced	  resulting	  in	  Pt-­‐DNA	  crosslinks.	  1,2-­‐intrastrand	  crosslinks	  (that	  are	  produced	  when	  Pt	  reacts	  with	  two	  adjacent	  guanines)	  are	  more	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common	  than	  the	  1,3-­‐intrastrand	  crosslinks	  (that	  result	  from	  the	  reaction	  of	  Pt	  with	  two	   non	   adjacent	   guanines	   with	   one	   nucleotide	   base	   in	   between).	   Interstrand	  crosslinks	  are	  rare	  and	  constitute	   less	  than	  5%	  of	  Pt-­‐DNA	  lesions.	  Pt-­‐DNA	  adducts	  interfere	  with	  DNA	  replication,	  transcription	  and	  cell	  division	  and	  ultimately	  induce	  apoptotic	  cell	  death.	  	  1.2. Platinum	  Resistance	  in	  Epithelial	  Ovarian	  Cancer	  	   Resistance	  to	  Pt-­‐based	  chemotherapeutic	  agents	  has	  been	  a	  major	  limitation	  for	   successful	   treatment	   for	   a	   wide	   variety	   of	   cancers.	   Epithelial	   ovarian	   cancer	  (EOC)	  is	  one	  of	  the	  most	  sensitive	  solid	  tumors	  to	  Pt-­‐based	  chemotherapy.	  	  However	  more	  than	  80%	  of	  the	  patients	  relapse	  with	  Pt-­‐resistant	  disease,	  where	  second	  line	  therapies	  are	  largely	  ineffective	  (5).	  Thus,	  clinicians	  have	  designated	  ovarian	  cancer	  as	   the	   most	   deadly	   gynecological	   cancer.	   In	   the	   past	   decade,	   there	   has	   been	   no	  significant	   improvement	   in	   the	   cure	   rate	  of	  ovarian	   cancer.	  Overall	   survival	   (6)	  of	  the	   patients	   has	   increased	   marginally	   due	   to	   better	   patient	   care	   and	   increase	   in	  choice	   for	   second	   line	   therapies,	   nonetheless	   progression	   free	   survival	   (PFS)	   still	  remains	  the	  same	  (7).	  The	  combination	  of	  carboplatin	  and	  paclitaxel	  continues	  to	  be	  the	  standard	  first	  line	  therapy	  for	  the	  treatment	  of	  EOC.	  Although	  a	  large	  number	  of	  second	  line	  therapies	  are	  available	  for	  patients	  relapsing	  with	  Pt-­‐resistant	  cancers,	  most	   of	   them	  have	   been	   effective	   only	   in	   small	   subsets	   of	   the	   patient	   population.	  There	   is	   a	   need	   to	   systematically	   evaluate	   many	   of	   these	   novel	   drugs	   as	   single	  agents	   or	   in	   combination	   with	   chemotherapy.	   The	   second	   line	   treatment	   options	  following	   recurrence	   are	   subdivided	   into	   two	   categories:	   1)	   retreatment	   with	  cisplatin	   or	   carboplatin	   for	   Pt	   sensitive	   recurrence	   (patients	   relapsing	   after	   6	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months	   post	   Pt-­‐based	   chemotherapy)	   2)	   Non	   Pt-­‐based	   drug	   therapy	   for	   Pt-­‐refractory	   or	   Pt-­‐resistant	   recurrence	   (patients	   relapsing	   during	   or	   less	   than	   6	  months	   post	   Pt-­‐based	   chemotherapy)	   (8).	   A	   number	   of	   drugs	   such	   as	   paclitaxel,	  doxorubicin,	  gemcitabine	  and	  bevacizumab	  have	  been	  used	  in	  trials	  as	  second	  line	  therapies	  for	  Pt-­‐resistant	  EOC	  with	  response	  rates	  from	  10-­‐35%	  (9).	  1.3. Platinum	  Resistance	  in	  Non-­‐Small	  Cell	  Lung	  Cancer	  	   Non-­‐small	   cell	   lung	   cancers	   (NSCLCs)	   are	   often	   intrinsically	   insensitive	   to	  chemotherapy	   (10).	   Moreover	   majority	   of	   the	   patients	   are	   diagnosed	   post	  metastasis	  making	   it	   difficult	   to	   use	   other	   treatment	   options	   such	   as	   surgery	   and	  radiation.	  However,	  whenever	  possible	  surgery	  is	  increasingly	  being	  combined	  with	  both	   pre-­‐operative	   (neo-­‐adjuvant	   chemotherapy)	   and	   post-­‐operative	   (adjuvant	  chemotherapy)	   chemotherapy	   involving	   cisplatin.	   The	   5-­‐year	   rate	   of	   OS	   in	   non-­‐small	   cell	   lung	  cancer	   (NSCLC)	  still	   remains	  below	  15%	  (10).	   	   	  The	  most	   common	  types	   of	   NSCLCs	   can	   be	   categorized	   into	   three	   types	   –	   adenocarcinoma	   (most	  common	  type	  of	   lung	  cancer	  and	  most	  typical	   in	  non	  smokers)	  and,	  squamous	  cell	  carcinoma	  (more	  common	  in	  men	  and	  correlated	  to	  smoking	  history)	  and	  large	  cell	  carcinoma	   (heterogeneous	   and	   less	   than	   10%	   of	   NSCLC)	   (6,11,12).	   A	   number	   of	  targeted	  therapies	  have	  been	  developed	  in	  the	  past	  for	  the	  treatment	  of	  lung	  cancers	  with	  specific	  genetic	  mutations.	  For	  example,	  drugs	  crizotinib	  and	  ceritinib	  targeting	  the	   ALK	   gene	   re-­‐arrangement.	   Other	   prominent	   drugs	   are	   the	   tyrosine	   kinase	  inhibitors	   such	   as	   gefitinib	   and	   erlotinib	   and	   angiogenesis	   inhibitor	   bevacizumab	  (13).	  Each	  of	   these	  has	  had	  minimal	   to	  moderate	   success	  depending	  on	   the	   target	  population	  (14).	   	  Moreover	  tumors	  that	  are	  resistant	  to	  one	  type	  of	  drug	  are	  often	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seen	  to	  be	  resistant	  to	  other	  drugs	  as	  well	  or	  in	  some	  cases	  acquire	  resistance	  over	  time	  to	  other	  drugs.	  Although	  numerous	  mechanisms	  have	  been	  delineated	  for	  drug	  resistance	  in	  lung	  cancer	  we	  are	  still	  far	  away	  from	  establishing	  effective	  strategies	  to	   overcome	   drug	   resistance.	   Thus,	   extensive	   targeting	   of	   underlying	   drug	  resistance	  mechanisms	  becomes	  utmost	  important.	  1.4. 	  Cisplatin	  –	  mechanism	  of	  action	  	   An	  understanding	  of	  the	  mode	  of	  action	  of	  cisplatin	  is	  cardinal	  for	  elucidating	  the	   different	   mechanisms	   leading	   to	   cisplatin	   resistance.	   As	   briefly	   mentioned	  earlier,	  cisplatin	  by	  itself	  is	  an	  inert	  molecule	  and	  it	  must	  be	  activated	  by	  a	  series	  of	  aquation	  reactions	  inside	  the	  cell.	  The	  aquation	  reactions	  involve	  the	  substitution	  of	  the	   chloride	   groups	   (one	   or	   both)	   with	   water	   molecules	   within	   the	   cell.	   The	  relatively	   low	   concentration	   of	   chloride	   ions	   inside	   the	   cytoplasm	   (~2-­‐10	  mM	   as	  compared	   to	  100	  mM	  in	  extracellular	  milieu)	   facilitates	   this	   reaction	   to	   take	  place	  spontaneously	   generating	  mono	   and	   bi-­‐aquated	   forms	   of	   cisplatin	   that	   are	   highly	  reactive	   (4).	   However	   it’s	   interesting	   to	   note	   that	   only	   1%	   of	   the	   intra-­‐cellular	  cisplatin	  actually	  hits	  its	  primary	  target	  –	  the	  nuclear	  DNA.	  The	  rest	  of	  the	  activated	  cisplatin	   molecules	   are	   subjected	   to	   a	   wide	   variety	   of	   cytoplasmic	   substrates,	  especially	   endogenous	   nucleophiles	   such	   as	   reduced	   glutathione	   (GSH)	   and	   other	  proteins	  with	  cysteine	  residues.	  This	  also	  has	  the	  potential	  to	  shift	  the	  redox	  balance	  inside	  the	  cell	  towards	  oxidative	  stress	  that	  can	  further	  facilitate	  DNA	  damage	  (15).	  Aquated	   cisplatin	   covalently	   binds	   DNA	  with	   a	   propensity	   for	   N7-­‐sites	   on	   purine	  bases	   and	   generates	   protein-­‐DNA	   complexes	   and	   intra-­‐	   and	   inter-­‐strand	   DNA	  adducts	  (Figure	  1).	  Guanine	  bases	  are	  preferred	  over	  adenine	   for	   the	   formation	  of	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coordinate	   covalent	   bonds.	   95%	   of	   the	   Pt-­‐DNA	   adducts	   constitute	   of	   intrastrand	  adducts,	   while	   interstrand	   adducts	   account	   for	   less	   than	   5%	   (Figure	   1).	   It’s	  noteworthy	  to	  point	  out	  that	  the	  active	  form	  of	  carboplatin,	  a	  cisplatin	  analogue,	  is	  identical	  to	  cisplatin	  and	  forms	  exactly	  the	  same	  type	  of	  DNA	  lesions	  (4).	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cisplatin	  (Figure	  2)	  (16-­‐18).	  Multiple	  repair	  pathways	  including	  nucleotide	  excision	  repair	   (NER),	   homologous	   recombination	   (HR)	   (including	   the	   fanconi	   anemia	  proteins)	  and	  mismatch	  repair	  (MMR)	  recognize	  cisplatin	  induced	  DNA	  lesions	  (5).	  The	  balance	  between	  DNA	  damage	  and	  DNA	  repair	  dictates	  tumor	  cell	  death	  (Figure	  2).	  If	  the	  extent	  of	  DNA	  damage	  is	  limited	  then	  the	  damage	  induced	  S	  and	  G2	  phase	  cell	   cycle	   arrest	   play	   a	   protective	   role	   by	   allowing	   time	   for	   repair	   and	  preventing	  aberrant	  mitosis.	  However	   if	   the	  extent	  of	  DNA	  damage	   is	  beyond	   repair	   the	   cells	  are	   programmed	   for	   apoptotic	   cell	   death.	   Current	   theories	   also	   implicate	   cell	  specific	   differences	   in	   repair	   versus	   apoptosis	   balance	   (19).	   The	   major	   signaling	  mechanism	  that	  translates	  cisplatin	  induced	  DNA	  damage	  to	  apoptosis	  involves	  the	  activation	   of	   the	   DNA	   damage	   regulators	   namely	   ataxia	   telangiectasia	   mutated	  (ATM)	   and	  RAD3-­‐related	  protein	   (ATR)	   (20),	   checkpoint	   kinases	   CHK1	   and	  CHK2	  and	  phosphorylation	  and	  stabilization	  of	  p53	  (Figure	  2)	  (4).	  p53	  activation	  signals	  mitochondrial	  permibilization	  by	  release	  of	  apoptogenic	  factors	  or	  increased	  death	  receptor	   signaling	  which	  ultimately	   lead	   to	   caspase	  activation	  and	  cell	  death.	  This	  process	  is	  further	  facilitated	  by	  binding	  of	  damage	  recognition	  proteins	  that	  bind	  to	  physical	  distortions	   in	  DNA	   induced	  by	   intrastrand	  Pt-­‐DNA	  adducts.	  Such	  proteins	  include	  components	  of	  MMR,	  the	  high	  mobility	  group	  of	  proteins	  (HMG),	  the	  human	  RNA	   polymerase	   I	   transcription	   ‘upstream	   binding	   factor’	   (hUBF),	   and	   the	  transcription	   factor	   ‘TATA	   binding	   protein’	   (TBP)	   (13).	   Cisplatin	   has	   also	   been	  shown	  to	  activate	  the	  mitogen-­‐activated	  kinase	  (MAPK)	  system	  pathways,	  however	  the	  relative	  contribution	  of	  these	  pathways	  to	  cisplatin	  cytotoxicity	  is	  unclear.	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via	   passive	   diffusion,	   the	   mode	   of	   transport	   for	   cisplatin	   into	   the	   cells	   has	   been	  linked	  to	  the	  copper	  transporter	  CTR1	  (21).	  A	  decrease	  in	  CTR1	  expression	  on	  the	  plasma	   membrane	   can	   reduce	   the	   intracellular	   uptake	   of	   cisplatin	   and	   hence	  contribute	   to	   platinum	   resistance.	   Similarly	   overexpression	   of	   ABC	   (ATP-­‐binding	  cassette)	   transporters	   (ex:	  MRP2	   (multidrug	   resistance	   protein-­‐2)	   and	   ATP7A	   (p-­‐type	   ATPase))	   that	   actively	   efflux	   cisplatin	   out	   of	   the	   cells	   may	   lead	   to	   platinum	  resistant	   cancers	   (22,23).	   Furthermore,	   increased	   cytoplasmic	   inactivation	   of	  cisplatin	   (after	   the	   aquation	   reaction)	   by	   nucleophilic	   scavengers	   such	   as	   GSH,	  methionine,	  metalothioneins	  and	  other	  cysteine	  rich	  proteins	  may	  drastically	   limit	  the	  active	  concentration	  of	  cisplatin	  within	  the	  cells,	  thus	  causing	  chemoresistance	  (15).	  	   The	   on-­‐target	   factors	   primarily	   include	   an	   altered	   capacity	   of	   repair	   and	  tolerance	  of	  the	  Pt-­‐DNA	  adducts.	  A	  series	  of	  DNA	  repair	  pathways	  have	  been	  linked	  to	   Pt-­‐resistance.	   NER	   is	   the	   major	   pathway	   for	   the	   removal	   of	   Pt-­‐DNA	   lesions	  (primarily	   intra-­‐strand	   crosslinks)	   and	   NER	   efficiency	   in	   many	   cancers	   has	   been	  directly	   correlated	   to	   platinum	   resistance	   (24,25).	   Conversely	   defects	   in	   this	  pathway	  have	  been	  linked	  to	  the	  platinum	  sensitivity	  in	  cancer	  cells	  (26).	  Proteins	  of	  the	  MMR	  pathway	  have	  been	  shown	  to	  recognize	  Pt-­‐DNA	   lesions	  but	   fail	   to	  repair	  such	   adducts	   and	  hence	  may	   signal	   a	   pro-­‐apoptotic	   cascade	   (27).	  Hence	   some	  Pt-­‐resistant	  cancers	  are	  associated	  with	  the	  deficiency	  of	  MMR	  proteins	  such	  as	  MSH2	  and	   MLH1,	   since	   the	   futile	   cycle	   of	   MMR	   contributes	   to	   killing	   mechanisms.	  Translesion	  synthesis,	  also	  known	  as	  replicative	  bypass	  is	  another	  mechanism	  that	  contributes	   to	   platinum	   resistance	  by	   tolerance	   of	   Pt-­‐DNA	   lesions	   (28).	   The	  DNA-­‐
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synthesis	   in	   this	   case	   is	   not	   stalled	   at	   the	   site	   of	   the	  DNA	   lesion,	   but	   instead	   just	  proceeds	  beyond	  the	  Pt-­‐adducts.	  The	  inter-­‐strand	  Pt-­‐DNA	  crosslinks	  are	  recognized	  by	   a	   group	   of	   fanconi	   anemia	   proteins	   that	   constitute	   the	   inter-­‐strand	   crosslink	  repair	   (ICR)	   pathway	   (29).	   Such	   crosslinks	   often	   result	   in	   a	   double	   strand	   break	  (DSB)	   and	   are	   further	   repaired	   by	   the	  HR	  pathway	   during	   the	   S-­‐phase	   of	   the	   cell	  cycle.	  HR	  also	  plays	  a	  crucial	  role	  in	  tolerance	  of	  both	  intra-­‐strand	  and	  inter-­‐strand	  Pt-­‐DNA	  adducts.	  Both	  ICR	  and	  HR	  status	  have	  been	  shown	  to	  correspond	  to	  cisplatin	  sensitivity	  and	  resistance	  (20,30,31).	  	  	   The	   post	   target	   platinum	   resistance	   can	   be	   due	   to	   a	   defect	   in	   signal	  transduction	  of	  the	  apoptotic	  cascade	  or	  due	  to	  a	  defect	  in	  the	  cell	  death	  machinery	  itself.	   p53	   status	   has	   been	   observed	   to	   be	   a	   powerful	   determinant	   of	   platinum	  sensitivity	   in	   a	   wide	   variety	   of	   cancers	   (32).	   Overexpression	   of	   anti-­‐apoptotic	  proteins	  such	  as	  BCL-­‐2,	  BCL-­‐XL	  and	  MCL-­‐1	  has	  been	  shown	  to	  confer	  resistance	  to	  Pt	  (33-­‐36).	  	  	   Finally,	   off-­‐target	   factors	   could	   contribute	   to	   the	   cisplatin	   resistant	  phenotype	   by	   alteration	   in	   signaling	   of	   pathways	   independent	   to	   cisplatin	   that	  however	  compensate	   for	   the	  cisplatin	   induced	  effects.	  For	  example,	  ERBB2/HER-­‐2	  overexpression	  and	  PI3K/AKT1	  activation	  has	  been	  linked	  to	  Pt-­‐resistance	  in	  NSCLC	  patients	  by	  promoting	  cell	  cycle	  arrest	  and	  allowing	  more	  time	  for	  repair	  of	  Pt-­‐DNA	  adducts	   (4).	   Dual-­‐specificity	   Y-­‐phosphorylation	   regulated	   kinase	   1B	   (DYRK1B)	   is	  overexpressed	   in	   solid	   tumors	   and	   its	   depletion	   sensitizes	   NSCLC	   and	   ovarian	  cancer	  cells	  to	  cisplatin	  due	  to	  increased	  oxidative	  stress	  (37).	  Deficiency	  in	  the	  pro-­‐apoptotic	   MAPK	   signaling	   has	   also	   been	   associated	   with	   cisplatin	   resistance,	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however	  no	  correlation	  exists	  between	  expression	  levels	  of	  MAPK	  family	  members	  and	  Pt-­‐sensitivity.	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of	  NER	  component	  excision	   repair	   cross-­‐complementing	  1	   (ERCC1)	  or	  ERCC1-­‐XPF	  has	  been	  associated	  with	  Pt-­‐resistance	   in	  NSCLC	   (24).	  Xeroderma	  pigmentosum	  A	  (XPA),	  another	  critical	  NER	  factor,	  was	  overexpressed	  in	  cisplatin	  resistant	  ovarian	  cancers	  and	  contributed	  to	  increased	  NER	  activity	  (38).	  	  	   HR	   is	   the	   other	   major	   pathway	   for	   both	   repair	   and	   tolerance	   of	   Pt-­‐DNA	  lesions.	  HR	  genes	  BRCA1	  and	  BRCA2	  are	  often	  mutated	  in	  a	  large	  number	  of	  breast	  and	   ovarian	   cancers.	   It’s	   well	   established	   that	   HR	   deficient	   cancers	   are	   more	  sensitive	  to	  cisplatin	  as	  compared	  to	  their	  HR	  proficient	  counterparts.	  For	  example,	  BRCA	  deficient	  cancers	  are	  generally	  more	  responsive	  to	  cisplatin	  and	  have	  a	  better	  prognosis	  (30).	  Conversely	  up-­‐regulation	  of	  BRCA1	  has	  been	  associated	  with	  repair-­‐mediated	   resistance	   to	   cisplatin	   (32).	   Furthermore,	   it	   has	   been	   shown	   that	  resistance	   can	   be	   acquired	   in	   certain	   BRCA	   deficient	   cancers	   that	   are	   initially	  sensitive	  to	  Pt	  treatment	  by	  certain	  accompanying	  mutations	  accumulated	  over	  time	  that	   restore	   the	   HR	   function	   by	   compensating	   for	   the	   BRCA	   deficiency	   (39,40).	  Taken	  together,	  HR	  status	  serves	  an	  independent	  marker	  of	  cisplatin	  sensitivity.	  	  1.7. RPA	  and	  its	  role	  in	  NER	  and	  HR	  
 RPA	  is	  the	  major	  human	  ssDNA	  binding	  protein	  and	  is	  required	  for	  both	  NER	  and	   HRR	   (41).	   The	   RPA	   heterotrimer	   consists	   of	   70	   kDa,	   32	   kDa	   and	   14	   kDa	  subunits	  (Figure	  4)	  with	  the	  70-­‐kDa	  subunit	  containing	  the	  two	  major	  high	  affinity	  DNA	  binding	  domains	  (DBD)	  DBD	  A	  and	  B,	  as	  well	  as	  DBD	  C	  and	  F.	  	  DBD	  D	  and	  E	  are	  in	  the	  32-­‐kDa	  and	  14-­‐kDa	  subunit,	  respectively.	  	  Binding	  to	  short	  stretches	  of	  ssDNA	  (~	   8-­‐10	   nucleotides	   (nts))	   is	   primarily	   mediated	   by	   DBD	   A	   and	   B,	   while	  intermediate	  length	  ssDNA	  (~	  12-­‐23	  nts)	  also	  involves	  DBD	  C.	  	  Longer	  length	  ssDNA	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(~	   28-­‐30	   nts)	   engages	   DBD	   D	   in	   addition	   to	   DBDs	   A,	   B	   and	   C	   (42-­‐44). 	   Recent	  reports	   however	   contest	   the	   conventional	   3	   distinct	   modes	   of	   binding	   for	   RPA.	  Crystal	  structure	  and	  x-­‐ray	  scattering	  studies	  suggest	  that	  RPA	  binding	  to	  ssDNA	  is	  stable	  in	  only	  two	  modes	  –	  the	  low	  affinity	  binding	  mode	  (8-­‐10	  nts	  involving	  DBD	  A	  and	  B)	  and	  the	  high	  affinity	  binding	  mode	  (28-­‐30	  nts	  involving	  DBD	  A,	  B,	  C	  and	  D)	  (45,46).	   	   Besides	   the	   RPA-­‐protein	   interactions	   are	   compatible	   only	   with	   the	   low	  affinity	  binding	  mode.	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   RPA	  plays	  essential	  and	  non-­‐redundant	  roles	  in	  both	  NER	  and	  HR,	  apart	  from	  its	   role	   in	   replication	   and	  DNA	   damage	   checkpoint	   activation. Each	   of	   these	   roles	  requires	  binding	  of	  RPA	  to	  ssDNA,	  making	  RPA-­‐DNA	  interactions	  a	  promising	  target	  for	   anti-­‐cancer	   therapeutic	   activity	   in	   combination	   with	   cisplatin	   (Figure	   5).	   RPA	  plays	  a	  critical	  role	  in	  the	  initial	  phase	  of	  HR	  by	  binding	  to	  ssDNA	  and	  preventing	  it	  to	   form	   secondary	   structures	   by	   self-­‐complementation	   or	   getting	   degraded	   by	  endonucleases	   (48).	   RPA	   bound	   ssDNA	   acts	   as	   a	   substrate	   for	   the	   formation	   of	   a	  nucleoprotein	  filament	  by	  Rad51	  and	  its	  cofactors,	  which	  further	  drives	  the	  process	  of	   HR	   mediated	   DNA	   repair	   (Figure	   5)	   (49).	   Moreover	   depletion	   of	   RPA	   protein	  inhibits	   RAD51	   foci	   formation	   and	   repair	   of	   double	   stranded	   breaks	   through	   HR	  (50).	   During	   NER,	   RPA	   binds	   ssDNA	   in	   the	   opened	   DNA	   complex	   (resulting	   from	  helical	  distortion	  by	  the	  intra-­‐strand	  DNA	  lesion	  or	  opening	  up	  of	  the	  damaged	  DNA	  bubble	  by	  TFIIH	  helicase	  activity)	  and	  helps	  in	  stabilization	  of	  the	  repair	  complex	  at	  the	   site	   of	   DNA	  damage	   (Figure	   5)	   (51).	   RPA	   bound	   to	   ssDNA	   also	   interacts	  with	  other	   NER	   proteins	   like	   XPA,	   XPG	   and	   XPF	   and	   helps	   in	   recruitment	   and	   proper	  positioning	  of	  the	  endonucleases	  (XPG	  and	  ERCCI-­‐XPF)	  that	  are	  responsible	  for	  the	  dual	  incisions	  around	  the	  DNA	  lesion.	  Additionally	  RPA	  not	  only	  acts	  during	  the	  pre-­‐incision	  steps	  but	  also	  remains	  bound	  to	  the	  ssDNA	  post	  excision	  and	  facilitates	  the	  gap-­‐filling	  repair	  synthesis	  by	  DNA	  polymerases.	  Furthermore	  in	  vitro	  reconstituted	  NER	  demonstrates	  RPA	   as	   absolutely	   essential	   for	   repair	   of	   Pt-­‐DNA	   adducts	   (52).	  Clearly	  RPA’s	   role	   is	  absolutely	   critical	   in	  both	   the	  DNA	  repair	  processes	  –HR	  and	  NER.	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Figure	  5:	  Role	  of	  RPA	  in	  NER,	  HRR	  and	  DNA	  replication.	  HRR	  indicates	  homologous	  recombination	  and	  repair.	  	  1.8. Chemical	  Synthetic	  Lethality	  in	  Conjunction	  with	  DNA	  Damage	  	   Structural	   analysis	   of	   RPA	   reveals	   unique	   protein-­‐DNA	   interactions	   that	  would	  facilitate	  the	  design	  of	  potent	  and	  selective	  small	  molecule	  inhibitors	  (SMIs)	  (46).	  	  It	  has	  been	  also	  shown	  that	  genetic	  mutants	  of	  RPA	  with	  defects	  in	  DNA	  repair	  function	   do	   not	   impact	   DNA	   replication	   and	   similarly	   some	   replication	   defective	  RPA	  mutants	  display	  DNA	  repair	  proficiency	  (41,53,54).	  	  This	  separation	  of	  function	  can	  be	  exploited	  by	  using	  chemical	  probes	   that	  exclusively	   interfere	  with	   the	  DNA	  repair	  pathway	  and	   that,	   in	  conjunction	  with	  DNA-­‐damaging	  agents,	  would	  offer	  a	  new	   possibility	   for	   cancer	   treatment.	   Our	   group	   has	   previously	   reported	   both	  reversible	   and	   irreversible	   chemical	   inhibitors	   of	   RPA	   (55-­‐58).	   	   The	   reversible	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inhibitor	  TDRL-­‐505	  exhibits	  synergistic	  effects	  with	  DNA	  damaging	  agents	  in	  a	  lung	  cancer	  cell	  model.	  	  This	  small	  molecule	  hinders	  the	  binding	  of	  DBD	  A	  and	  B	  of	  RPA	  to	  ssDNA,	  which	  according	  to	   in	  silico	  docking	  analysis	  occurs	  as	  a	  consequence	  of	  its	  interaction	   with	   DBD	   B	   and	   the	   DBD	   A-­‐B	   interdomain	   (58).	   Therefore,	   for	   the	  present	  study,	  we	  screened	  TDRL-­‐505	  along	  with	  a	  series	  of	  analogs	  and	  evaluated	  their	   activity	   in	   an	   EOC	   cell	   culture	  model.	   	   SAR	  data	   led	   us	   to	   an	   optimized	   lead	  compound,	  TDRL-­‐551.	  	  Herein	  we	  report	  the	  in	  vitro,	  cellular	  and	  in	  vivo	  activity	  of	  TDRL-­‐551	  in	  models	  of	  lung	  and	  ovarian	  cancer.	  Our	  model	  (Figure	  6)	  represents	  an	  artificial	  system	  of	  synthetic	  lethality	  with	  our	  inhibitors	  impairing	  a	  critical	  protein	  function	   that	   is	   synergistically	   lethal	   in	   combination	   with	   DNA	   damaging	   agents.	  Since	  RPA	   inhibition	  disrupts	  both	  NER	  and	  HR	  –	   the	  major	  pathways	   for	  Pt-­‐DNA	  repair,	   its	   combination	   therapy	   with	   platinum	   has	   immense	   potential	   for	   the	  treatment	  of	  a	  wide	  variety	  of	  cancers.	  	  	  	  
	   16	  
	  
Figure	   6:	   Model	   for	   synthetic	   lethality	   with	   RPA	   inhibitors	   (RPAi)	   and	   platinum	  (Pt).	  	  	  	  	  	  	  	  	  	  	  	  	  














	   17	  
2. MATERIALS	  AND	  METHODS	  2.1. Electrophoretic	  Mobility	  Shift	  Assays	  (EMSA)	  2.1.1. General	  	   Human	  RPA	  was	  expressed	   in	  E.	  coli	   and	  purified	  by	  affinity	  purification	  as	  previously	  described	  (40).	  	  20	  μL	  EMSA	  reactions	  were	  performed	  with	  50	  nM	  RPA	  and	  2.5	  nM	  5’[32P]-­‐labeled	  34-­‐base	  DNA	  in	  buffer	  containing	  20mM	  HEPES	  (pH	  7.0),	  1mM	  DTT,	  0.001%	  NP-­‐40,	  100	  mM	  NaCl,	  5	  mM	  MgCl2	  and	  50	  μg/ml	  bovine	  serum	  albumin.	   Chemical	   compounds,	   either	   purchased	   from	  ChemDiv	   or	   synthesized	   in	  our	  laboratory,	  were	  suspended	  in	  DMSO	  and	  titrated	  as	  detailed	  in	  each	  figure.	  	  The	  DMSO	  concentration	  in	  the	  reaction	  mixture	  was	  kept	  constant	  at	  5%	  or	  below.	  RPA	  in	  the	  reaction	  buffer	  was	  incubated	  with	  inhibitor/DMSO	  for	  30	  minutes	  before	  the	  addition	  of	  DNA.	  This	  was	   followed	  by	  5	  minutes	  of	  post	  DNA	  incubation	  for	  RPA-­‐DNA	   binding.	   Reactions	   were	   carried	   out	   at	   room	   temperature	   and	   6%	   native	  polyacrylamide	  gels	  were	  used	  to	  separate	  the	  products.	   	  The	  bound	  and	  unbound	  fractions	  were	  then	  quantified	  by	  phosphor-­‐imager	  analysis	  using	  the	   ImageQuant	  software	  (Molecular	  Dynamics,	  CA).	  
2.1.2. DNA	  Radiolabeling	  	   The	   DNA	   radiolabelling	   reaction	   mixture	   contained	   10	   pmols	   of	   34-­‐base	  DNA,	  20	  pmols	  of	  γ-­‐P32	  ATP,	  1X	  T4	  PNK	  Buffer	  and	  10	  units	  of	  T4	  PNK.	  Water	  was	  added	   to	  make	   up	   the	   reaction	   volume	   to	   50	   μl.	   The	   above	   reaction	  mixture	  was	  incubated	   at	   37°C	   for	   30	   mins.	   In	   order	   to	   ensure	   that	   the	   DNA	   was	   uniformly	  phosphorylated,	  1	  ul	  of	  ATP	  (1mM)	  was	  added	  to	  the	  50	  ul	  reaction	  and	  incubate	  for	  5	  min	  at	  37°C.	  4	  ul	  of	  EDTA	  was	  added	  to	  stop	  the	  reaction	  and	  incubated	  at	  70°C	  for	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5	  mins.	  The	  total	  reaction	  volume	  became	  55	  ul.	  So	  we	  had	  10	  pmol	  of	  DNA	  in	  55	  ul	  reaction.	  1	  ul	  of	   reaction	  was	  diluted	  1:10	  and	  1	  ul	  of	   this	  dilution	  was	   taken	  and	  spotted	  on	  DE81	  filter	  paper	  and	  dried.	  The	  spotted	  filter	  paper	  was	  washed	  3x	  with	  0.5M	   PO4	   pH	   7.0	   (~10ml),	   dried	   and	   counted	   in	   scintillation	   counter	   with	  scintillation	   fluid.	   The	   specific	   activity	   for	   the	   kinase	   reaction	   was	   calculated	   as	  follows:	  Specific	   activity	   =	   (CPM1*dilution*total	   reaction	   volume)/total	   pmols	   of	   DNA	   =	  CPM/pmol	  DNA	  	   G-­‐50	   columns	  were	  made	  with	  glass	  beads	  on	  bottom	  of	  0.5	  ml	   tubes	  with	  hole	   in	   it.	   The	   rest	   of	   the	   tubes	   were	   filled	   with	   G50	   matrix.	   The	   tubes	   were	  centrifuged	  for	  5	  mins	  at	  1000g.	  The	  best	  column	  was	  selected	  out	  of	  a	  sample	  of	  4-­‐6	  on	  visual	  inspection	  for	  cracks	  in	  the	  column.	  	   All	  remaining	  54	  ul	  of	  the	  remaining	  DNA	  labeling	  reaction	  mix	  was	  added	  to	  the	  selected	  minicolumn.	  This	  column	  was	  then	  centrifuged	  for	  5	  mins	  at	  1000	  g.	  1	  ul	  of	  purified	  DNA	  was	  diluted	  1:10	  and	  1	  ul	  of	  this	  dilution	  was	  taken	  and	  spotted	  on	  DE81	  filter	  paper.	  The	  filter	  paper	  was	  dried	  and	  counted	  on	  scintillation	  counter	  with	  scintillation	  fluid.	  The	  DNA	  concentration	  was	  determined	  as	  follows:	  DNA	  Concentration	  =	  CPM2*10/Specific	  Activity.	  2.1.3. EMSA	  with	  RPA-­‐A/B	  Box	  	   The	   RPA-­‐A/B	   construct	   was	   expressed	   as	   a	   SUMO-­‐His6-­‐RPA181-­‐432	   fusion	  protein.	  	  E.	  coli	  BL21	  (DE3)	  cells	  in	  log	  growth	  were	  induced	  for	  3	  hours	  with	  0.5mM	  IPTG	  at	  37°C.	  The	  cells	  were	  lysed	  in	  buffer	  containing	  50mM	  Tris	  pH	  7.5,	  300	  mM	  NaCl,	   10%	   sucrose,	   10mM	   imidazole,	   25	   μg/ml	   lysozyme,	   1	   μg/ml	   leupeptin,	   1	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μg/ml	  pepstatin	   and	  0.5	  mM	  PMSF.	  The	   lysate	  was	   loaded	  onto	   a	  Ni-­‐NTA	   column	  washed	   and	   then	   incubated	   overnight	  with	  wash	   buffer	   containing	   3	   μg/ml	  ULP1	  protease	   to	   cleave the	   SUMO	   tag.	  The	   cleaved	  His6-­‐RPA181-­‐432	  was	   eluted	   from	   the	  Ni-­‐NTA	  column	  with	  elution	  buffer	  containing	  350	  mM	  imidazole.	  The	  His6-­‐RPA	  was	  then	   further	  purified	  on	  a	   size	   exclusion	   column	   to	   remove	   the	   cleaved	  SUMO	   tag	  fragment.	  The	  elute	  pool	  from	  the	  size	  exclusion	  column	  was	  then	  concentrated	  and	  stored	   at	   -­‐80oC. The	   EMSA	   reactions	   contained	   125	   nM	   RPA-­‐A/B	   Box	   in	   20	   ul	  reactions	   and	   the	   gel	   was	   pre-­‐chilled	   and	   ran	   at	   4°	   C.	   The	   rest	   of	   the	   reaction	  conditions	  were	  identical	  to	  as	  described	  above	  in	  the	  general	  section.	  2.2. Chemical	  Synthesis	  2.2.1. General	  All	   solvents	   and	   chemicals	   were	   used	   as	   purchased	   from	   commercial	  suppliers.	   	   1H	  NMR	   spectra	  were	   obtained	   on	   a	   Bruker	   Avance	   III	   500	  MHz	  NMR	  spectrometer.	   	  Chemical	  shifts	  are	  expressed	  in	  parts	  per	  million	  (ppm,	  d),	  relative	  to	   tetramethylsilane	   (TMS)	   as	   internal	   reference.	   	   Signals	   are	   described	   as	   s	  (singlet),	  d	  (doublet),	  dd	  (doublet	  of	  doublets),	  dt	  (doubles	  of	  triplets),	  t	  (triplet),	  q	  (quartet),	  or	  p	  (pentet).	  
2.2.2. 2-­‐chloro-­‐7-­‐ethoxy-­‐3-­‐(3-­‐(4-­‐iodophenyl)-­‐4,5-­‐dihydro-­‐1H-­‐pyrazol-­‐5-­‐
yl)quinoline	  (7a,	  Figure	  5)	  NaOH	   (0.83	   mL,	   2.5	   M	   in	   water,	   2.07	   mmol)	   was	   added	   dropwise	   to	   a	  solution	   of	   4-­‐iodoacetophenone	   (0.36	   g,	   1.47	   mmol)	   and	   2-­‐chloro-­‐7-­‐ethoxyquinoline-­‐3-­‐carbaldehyde	  (0.35	  g,	  1.47	  mmol)	  in	  EtOH	  (12	  mL).	  	  After	  stirring	  for	  a	  45	  min	  at	  40	  oC,	  the	  reaction	  mixture	  was	  quenched	  with	  HCl	  (1.38	  mL,	  3	  M).	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The	   crude	   mixture	   containing	   the	   resulting	   enone	   was	   then	   filtered,	   thoroughly	  washed	   with	   EtOH,	   and	   used	   in	   the	   next	   step	   without	   further	   purification.	  	  Hydrazine	  monohydrate	  (0.36	  mL,	  7.33	  mmol)	  was	  added	  dropwise	  to	  a	  suspension	  of	   the	   enone	   obtained	   in	   the	   previous	   step	   in	   EtOH	   (30	   mL).	   	   The	   mixture	   was	  refluxed	   for	   1.5	   h	   with	   stirring,	   after	   which	   it	   was	   allowed	   to	   cool	   to	   room	  temperature.	   	   The	   obtained	   solid	   was	   filtered	   and	   washed	   with	   EtOH.	   	   Further	  purification	  by	   trituration	  with	  EtOH	  furnished	  the	   title	  compound	  as	  an	  off-­‐white	  solid	  (0.57	  g,	  81%	  over	  2	  steps).	   	  1H	  NMR	  (500	  MHz,	  DMSO-­‐d6)	  d	  1.41	  (t,	   J=7.0	  Hz,	  3H),	  2.89	  (dd,	  J=16.5,	  10.0	  Hz,	  1H),	  3.67	  (dd,	  J=16.5,	  11.0	  Hz,	  1H),	  4.20	  (q,	  J=7.0	  Hz,	  2H),	  5.19	  (dt,	  J=10.5,	  3.5	  Hz,	  1H),	  7.27	  (dd,	  J=9.0,	  2.5	  Hz,	  1H),	  7.34	  (d,	  J=2.5	  Hz,	  1H),	  7.44	  (d,	  J=8.5	  Hz,	  2H),	  7.74	  (d,	  J=8.5	  Hz,	  2H),	  7.84	  (d,	  J=3.5	  Hz,	  1H),	  7.97	  (d,	  J=9.0	  Hz,	  1H),	  8.42	  (s,	  1H).	  
2.2.3. 4-­‐(5-­‐(2-­‐chloro-­‐7-­‐ethoxyquinolin-­‐3-­‐yl)-­‐3-­‐(4-­‐iodophenyl)-­‐4,5-­‐dihydro-­‐1H-­‐
pyrazol-­‐1-­‐yl)-­‐4-­‐oxobutanoic	  acid	  	  (9a	  or	  TDRL-­‐551,	  Figure	  5)	  A	  round-­‐bottom	  flask	  coupled	  with	  a	  reflux	  condenser	  and	  containing	  a	  dry	  mixture	   of	   2-­‐chloro-­‐7-­‐ethoxy-­‐3-­‐(3-­‐(4-­‐iodophenyl)-­‐4,5-­‐dihydro-­‐1H-­‐pyrazol-­‐5-­‐yl)quinoline	  (7a)	  (0.6	  g,	  1.25	  mmol)	  and	  glutaric	  anhydride	  (0.14	  g,	  1.25	  mmol)	  was	  immersed	  into	  a	  preheated	  oil	  bath	  (65	  oC).	  	  CHCl3	  (24	  mL)	  was	  then	  added	  through	  the	   condenser	   in	   one	   portion.	   	   The	   resulting	   solution	  was	   refluxed	   for	   1.5	   h	  with	  stirring,	  after	  which	  it	  was	  allowed	  to	  cool	  to	  room	  temperature.	  	  The	  obtained	  solid	  was	  filtered	  and	  washed	  with	  ethyl	  acetate.	  	  Further	  purification	  by	  trituration	  with	  ethyl	  acetate	  yielded	  acid	  9a	  as	  an	  off-­‐white	  solid	  (0.53	  g,	  72%).	  	  1H	  NMR	  (500	  MHz,	  DMSO-­‐d6)	  d	  1.40	  (t,	  J=7.0	  Hz,	  3H),	  1.83	  (p,	  J=7.5	  Hz,	  2H),	  2.30	  (t,	  J=7.5	  Hz,	  2H),	  2.82	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(dt,	   J=15.0,	  7.5	  Hz,	  1H),	  2.91	   (dt,	   J=15.0,	  7.5	  Hz,	  1H),	  3.28	   (dd,	   J=18.0,	  5.5	  Hz,	  1H),	  3.97	  (dd,	   J=18.0,	  12.0	  Hz,	  1H),	  4.19	  (q,	   J=7.0	  Hz,	  2H),	  5.83	  (dd,	   J=12.0,	  5.5	  Hz,	  1H),	  7.26	   (dd,	   J=9.0,	   2.5	  Hz,	   1H),	   7.35	   (d,	   J=2.5	  Hz,	   1H),	   7.57	   (d,	   J=8.5	  Hz,	   2H),	   7.84	   (d,	  J=8.5	  Hz,	  2H),	  7.93	  (d,	  J=9.0	  Hz,	  1H),	  7.99	  (s,	  1H),	  12.09	  (s,	  1H).	  	  	  2.3. Cell	  Culture	  A2780	   cells	   and	  A2780/R	   cells	  were	   purchased	   from	   Sigma.	   	   All	   other	   cell	  lines	  were	   from	  ATCC	   and	   routinely	   tested	   for	  mycoplasma	   contamination.	   	   Cells	  were	   maintained	   in	   RPMI	   media	   supplemented	   with	   10%	   FBS,	   penicillin	   and	  streptomycin.	   	   Cultures	  were	   incubated	   at	   37	   °C	   in	   5%	  CO2	   and	   sub-­‐cultured	   2-­‐3	  times	  per	  week.	  	  	  	  	  	  
2.3.1. Clonogenic	  survival	  assays	  Cells	   were	   plated	   in	   a	   6	   well	   (100,000	   cells/well)	   or	   24	   well	   (25,000	  cells/well)	  plate,	  incubated	  for	  at	  least	  18	  hours	  and	  then	  treated	  with	  Pt/etoposide	  and/or	  RPA	  inhibitors.	   	  After	  48	  hours	  of	  treatment,	  the	  cells	  were	  re-­‐plated	  in	  10	  cm	   dishes	   (500-­‐1000	   cells/dish)	   and	   incubated	   for	   8-­‐10	   days	   to	   allow	   colony	  formation.	   	   Plates	   were	   then	   washed	   with	   PBS,	   fixed	   with	   glutaraldehyde	   and	  stained	   with	   crystal	   violet.	   	   The	   colonies	   were	   then	   counted	   using	   an	   Acolyte	  Synbiosis	  colony	  counter.	  	  	  	  
2.3.2. Assessment	  of	  synergy	  via	  combination	  index	  In	   the	   combination	   index	   studies,	   the	   A2780	   cells	   were	   treated	   with	   RPA	  inhibitor	  and	  Pt/etoposide	  alone	  as	  well	  as	  the	  combination	  of	  both	  –	  the	  inhibitor	  and	   the	   DNA	   damaging	   chemotherapeutic	   agent.	   	   The	   range	   of	   treatment	   was	  dependent	  on	  the	  IC50	  of	  each	  inhibitor/drug.	  	  If	  the	  IC50	  was	  X,	  then	  the	  cells	  were	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treated	  at	  a	  range	  of	  X/4	  to	  3X	  concentration	  in	  a	  colony	  formation	  assay.	   	  The	  kill	  curves	  from	  both	  the	  single	  agent	  treatments	  as	  well	  as	  the	  combination	  treatment	  were	  used	  in	  a	  Chou-­‐Talalay	  based	  method	  to	  determine	  the	  combination	   index	  at	  different	  fractions	  of	  cells	  affected	  (59,60).	   	  A	  CI	  >	  1	  indicates	  antagonism	  between	  the	  two	  agents,	  while	  a	  CI	  <	  1	  indicates	  synergy.	  	  A	  CI	  of	  1	  demonstrates	  an	  additive	  effect.	  2.4. Compound-­‐DNA	  binding	  assay	  A	   competitive	   DNA	   intercalation	   assay	   was	   performed	   using	   SYBR-­‐Green.	  	  Reactions	  were	   carried	   out	   in	   25	  mM	  MOPS	   (pH	  6.5)	   containing	   30	  μM	   sonicated	  salmon	   sperm	   DNA,	   SYBR-­‐Green	   and	   varying	   concentrations	   of	   RPA	   inhibitors.	  	  Reactions	   were	   performed	   in	   a	   black	   96-­‐well	   plate	   in	   a	   final	   volume	   of	   110	   μl.	  	  Doxorubicin,	  a	  known	  non-­‐covalent	  DNA	  binding	  chemotherapeutic,	  was	  used	  as	  a	  positive	  control.	  	  Fluorescence	  was	  measured	  using	  a	  BioTek®	  SynergyTM	  H1	  hybrid	  multi-­‐mode	  microplate	   reader	  with	  an	  excitation	  wavelength	  of	  485	  nm,	   emission	  wavelength	   of	   528	   nm	   and	   a	   read	   height	   of	   7	   mm.	   	   Data	   were	   collected	   using	  BioTek®	   Gen5TM	   reader	   software.	   	   Reactions	   were	   incubated	   a	   maximum	   of	   5	  minutes	  before	  measurements	  were	  collected.	  	  	  2.5. In	  vivo	  Analysis	  of	  TDRL-­‐551	  Non-­‐obese	   diabetic/severe	   combined	   immunodeficient	   mice	   (NOD/SCID)	  were	   obtained	   from	   The	   Jackson	   Laboratory	   (http://www.jax.org).	   	   	   All	   animal	  studies	  were	  conducted	  under	  the	  guidelines	  of	  the	  NIH	  and	  were	  approved	  by	  the	  Institutional	   Animal	   Care	   and	   Use	   Committee	   of	   Indiana	   University	   School	   of	  Medicine.	  	  Animals	  were	  maintained	  under	  pathogen-­‐free	  conditions	  and	  a	  12-­‐hour	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light-­‐dark	   cycle.	   	   The	   safety	   and	   tolerability	   of	   TDRL-­‐551	   was	   assessed	   in	   naïve	  NOD/SCID	  mice.	  	  Mice	  were	  treated	  IP	  with	  increasing	  concentrations	  of	  TDRL-­‐551	  in	   a	   formulation	   consisting	   of	   20%	   DMSO,	   10%	   Tween	   80,	   70%	   PBS.	   	   Based	   on	  preliminary	   metabolic	   profile	   and	   a	   half-­‐life	   of	   ~7	   hours	   (data	   not	   shown)	   we	  administered	   3	   doses	   per	   week	   for	   two	  weeks	   and	  measured	   body	  weight	   every	  other	  day.	  	  	  	   To	   assess	   anti-­‐cancer	   efficacy	   the	   hind	   flanks	   of	   sixty	   8-­‐10	  week	   old	  mice	  were	   implanted	  with	  2	  x	  106	  H460	  NSCLC	  cells	   in	  matrigel.	   	  Tumor	  volumes	  were	  monitored	   by	   caliper	   measurement	   [tumor	   volumes	   =	   length	   x	   (perpendicular	  width)2	  x	  0.5].	   	  Mice	  with	   tumors	  ranging	  between	  32-­‐152.5mm3	  8	  days	   following	  implantation	  were	  randomized	  into	  4	  treatment	  arms.	  	  Carboplatin	  was	  dissolved	  in	  water	  and	  administered	  via	  intraperitoneal	  injection	  at	  50	  mg/kg	  on	  days	  8,	  14,	  and	  20	   following	   implantation.	   	   TDRL-­‐551	  was	   suspended	   in	   20%	  DMSO,	   10%	  Tween	  80,	  70%	  PBS	  and	  administered	  via	  intraperitoneal	  injection	  at	  200	  mg/kg	  biweekly	  on	   days	   8,	   10,	   14,	   17,	   and	   20.	   	   Vehicle	   controls	   were	   administered	   to	   arms	   not	  receiving	   indicated	   treatments.	   	   Tumor	   volumes	   were	   monitored	   biweekly	   as	  indicated	   and	   the	   results	   are	   presented	   as	   the	   average	   tumor	   volume	   ±	   standard	  error	  of	  the	  mean	  for	  each	  group	  (n=14	  per	  group).	  2.6. Statistics	  
2.6.1. Tolerability	  of	  TDRL-­‐551	  in	  NOD/SCID	  mice.	  	  	  	   Student’s	   t	   test	   from	   Sigmaplot	   was	   used	   to	   test	   for	   any	   statistically	  significant	   difference	   in	   the	   overall	   change	   in	   body	   weight	   for	   NOD/SCID	   mice	  between	   each	   of	   the	   TDRL-­‐551	   doses	   and	   the	   vehicle	   treated	   control.	   Three	  mice	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were	  tested	  for	  each	  dosage	  group	  (n=3).	  Each	  of	  the	  data	  points	  (days	  1,	  3,	  5,	  9,	  11,	  15,	  18)	  for	  each	  of	  the	  dosage	  arms	  were	  compared	  to	  the	  corresponding	  data	  points	  in	   the	   vehicle	   treated	   control.	   An	   alpha	   of	   0.05	  was	   used	   to	   determine	   statistical	  significance.	  
2.6.2. In	  vivo	  anti-­‐cancer	  activity	  of	  TDRL-­‐551.	  	  	  	   Unpaired	  one-­‐tailed	   student’s	   t	   test	   from	  Sigmaplot	  was	  used	   to	  determine	  statistically	   significant	   difference	   in	   the	   tumor	   volumes	   between	   each	   of	   the	  treatment	  arms	  at	  the	  following	  data	  points	  –	  day	  8,	  10,	  14,	  17,	  20	  and	  21.	  Fourteen	  mice	  were	   used	   for	   each	   of	   the	   treatments	   (n=14).	   An	   alpha	   of	   0.05	  was	   used	   to	  determine	  statistical	  significance.	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3. RESULTS	  3.1. Screening	  TDRL-­‐505	  analogs	  	   Toward	  improving	  the	  potency	  and	  physiochemical	  properties	  of	  TDRL-­‐505,	  we	  screened	  26	  compounds	  selected	  on	   the	  basis	  of	  structural	  similarity	   to	  assess	  their	  ability	   to	   inhibit	  RPA-­‐DNA	  binding	  activity.	   	  These	  26	  compounds	  shared	  the	  same	   2-­‐pyrazoline	   core	   structure	   as	   TDRL-­‐505,	   but	   differed	   in	   either	   the	  type/length	  of	  the	  side	  chain	  attached	  to	  N1,	  the	  substitution	  of	  the	  phenyl	  group	  at	  C3,	  or	  the	  type	  of	  aromatic	  ring	  at	  C5.	   	  Data	  from	  the	  26	  compounds	  are	  shown	  in	  Figures	  7A	  and	  8A	  along	  with	  quantification	  of	  the	  data	  in	  Figures	  7B	  and	  8B.	  	  Each	  of	   the	   analogs	   that	   displayed	   inhibitory	   activity	   towards	   RPA	  was	   titrated	   over	   a	  range	  of	  concentrations	   to	  determine	   IC50	  values	  (Figures	  7C	  and	  8C).	   	  These	  data	  were	   used	   to	   determine	   SAR.	   	   We	   identified	   three	   important	   aspects	   of	   the	  molecules:	   the	   length	  of	   the	  carboxylic	  acid	  chain,	   the	  halogen	  on	   the	  phenyl	   ring,	  and	  the	  alkyl	  ether	   in	   the	  quinoline	  ring	  (Figure	  9).	   	  Consequently,	  we	  pursued	  an	  organic	   synthesis	   scheme	   to	   prepare	   additional	   TDRL-­‐505	   analogs	   and	   further	  interrogate	  the	  structure	  activity	  relationships.	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Figure	   7:	   EMSA	  screening	  of	  TDRL-­‐505	  analogs-­‐I.	   (A)	  12	  TDRL-­‐505	  analogs	  were	  screened	  using	  the	  EMSA	  assay	  for	  RPA-­‐DNA	  inhibition	  activity	  at	  100	  µM.	  	  The	  free	  DNA	  and	  RPA-­‐DNA	  complexes	  are	  indicated.	   	  The	  *	   indicated	  the	  position	  of	  the	  E.	  	  coli	   SSB-­‐DNA	   complex.	   	   Quantification	   of	   duplicate	   determinations	  were	   averaged	  and	  plotted	  as	  a	  percent	  of	  control	  with	  bars	  representing	  the	  range	  of	  values.	   (C)	  Structures	  of	  compounds	  with	  their	  corresponding	  IC50	  values	  (µM)	  calculated	  from	  EMSA	  reactions	  as	  described	  in	  Methods.	  Compounds	  were	  titrated	  at	  a	  range	  of	  1-­‐125	  μM.	  Compounds	  indicated	  with	  circles	  in	  ‘A’	  and	  ‘B’	  gave	  us	  our	  key	  preliminary	  findings	  in	  SAR	  studies.	  The	  horizontal	  line	  in	  ‘B’	  represents	  an	  80%	  cut-­‐off.	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Figure	  8:	  EMSA	  screening	  of	  TDRL-­‐505	  analogs-­‐II.	  (A)	  14	  TDRL-­‐505	  analogs	  were	  screened	   using	   the	   EMSA	   assay	   for	   RPA-­‐DNA	   inhibition	   activity	   at	   100	   µM	   as	   in	  Figure	  2	  A.	  	  Quantification	  of	  duplicate	  determinations	  were	  averaged	  and	  plotted	  as	  a	   percent	   of	   control	  with	   bars	   representing	   the	   range	   of	   values.	   (C)	   Structures	   of	  compounds	   with	   their	   corresponding	   IC50	   values	   (µM)	   calculated	   from	   EMSA	  reactions	  as	  described	  in	  Methods.	  Compounds	  were	  titrated	  at	  a	  range	  of	  1-­‐125	  μM.	  	  The	  horizontal	  line	  in	  ‘B’	  represents	  an	  80%	  cut-­‐off.	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Figure	   9:	   Structural	   components	   of	   TDRL-­‐505	   important	   for	   potent	   inhibition	   of	  RPA-­‐DNA	   interaction.	   The	   three	   circles	   highlight	   three	   different	   aspects	   of	   the	  structure	   of	   the	   small	   molecule	   inhibitor	   that	   were	   found	   to	   be	   important	   in	   the	  EMSA	  based	  SAR	  studies.	  	   3.2. Chemistry	  	   The	  synthetic	  approach	  developed	  for	  the	  preparation	  of	  TDRL-­‐505	  analogs	  is	   depicted	   in	   Figure	   10	   and	   involved	   5	   steps.	   Quinolines	   carbaldehydes	   4	   were	  prepared	   by	   acylation	   of	   alkoxyanilines	   2	   with	   acetic	   anhydride	   1,	   followed	   by	  Vilsmeier-­‐Haack	   formylation	   (61).	   	   Aldol	   condensation/dehydration	   with	   a	  corresponding	   methyl	   ketone	   5	   and	   sodium	   hydroxide	   yielded	   enones	   6,	   which,	  upon	  treatment	  with	  hydrazine,	  afforded	  2-­‐pyrazolines	  7.	  	  Lastly,	  acylation	  at	  N1	  of	  the	  pyrazoline	  core	  with	  a	  cyclic	  anhydride	  8	  furnished	  oxoacids	  9.	  The	  list	  of	  all	  the	  synthesized	  TDRL-­‐505	  analogs	  is	  shown	  in	  Table1.	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Figure	   10:	   Synthesis	   of	   TDRL-­‐505	   analogs.	   	   Reagents	   and	   conditions:	   (a)	   DIEA,	  DMAP,	  DCM,	  rt,	  2	  h,	  90-­‐100%.	  	  	  (i)	  DMF,	  POCl3,	  0	  oC,	  20	  min,	  (ii)	  Amide,	  110	  oC,	  2.5	  h,	  44-­‐64%.	  	  (c)	  NaOH	  10%,	  EtOH,	  45	  oC,	  45	  min.	  	  (d)	  H2N-­‐NH2.H2O,	  EtOH,	  reflux,	  1.5	  h,	  73-­‐81%	  (over	  2	  steps).	  	  (e)	  CHCl3,	  reflux	  1.5	  h,	  40-­‐72%.	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Table	  1:	   In	  vitro	  and	  cellular	   IC50	  values	  of	  TDRL-­‐505	  and	   its	  analogs.	  The	   in	  vitro	  IC50	   values	   are	   based	   on	   EMSA	   reactions	   as	   described	   in	   Methods.	   RPA	   was	  incubated	   with	   the	   above	   compounds	   at	   concentration	   range	   of	   1-­‐125	   μM.	   The	  cellular	   IC50	   values	   are	   calculated	   from	   clonogenic	   survival	   assays	   as	   described	   in	  Methods.	  The	  cells	  were	  treated	  with	  the	  above	  compounds	  at	  a	  concentration	  range	  of	   1-­‐200	   μM.	   Only	   four	   compounds	   were	   tested	   for	   cellular	   activity,	   the	   rest	   are	  indicated	   with	   ‘na’	   meaning	   data	   not	   available	   since	   the	   experiments	   were	   not	  performed.	  	  	  	  
 !
ENTRY!  !COMPOUND!
 !  !Y!  !R!  !n!  !In vitro IC50 !(µM)!  !Cellular IC50 !(µM)!
1! TDRL-505! p-Br! Et! 1! 38! >50!
2! TDRL-533! p-Br! Me! 1! >50! >50!
3! TDRL-540! p-F! Me! 1! >100! ---!
4! TDRL-543! p-Br! Et! 2! 25! 50!
5! TDRL-539! p-F! Me! 2! >100! ---!
6! TDRL-534! p-Br! Me! 2! 35! ---!
7! TDRL-556! p-Br! iPr! 2! 43! ---!
8! TDRL-551! p-I! Et! 2! 18! 25!
9! TDRL-557! p-F3CO! Et! 2! 30! ---!
10! TDRL-652! m-I! Et! 2! 15! ---!
11! TDRL-617! See below! >100! ---!
12! TDRL-634! See below! >100! ---!
Table&1:&In#vitro#and&cellular&IC50&values&of&TDRL9505&and&its&
analogs.!
	   31	  
3.3. In	  vitro	  inhibition	  of	  RPA’s	  DNA	  binding	  activity	  The	   in	   vitro	   inhibition	   of	   RPA’s	   DNA	   binding	   activity	   was	   determined	   by	  titrating	  all	   synthesized	  TDRL-­‐505	  analogs	  over	  a	   range	  of	   concentrations	   from	  0-­‐125	  μM	  in	  an	  EMSA	  based	  assay	  (Table	  1).	  	  We	  observed	  a	  slight	  increased	  potency	  by	  addition	  of	  a	  methylene	  group	  to	  the	  oxocarboxylic	  acid	  moiety	  (entries	  1	  and	  4,	  
and	  2	  and	  6).	  	  Additionally,	  we	  found	  a	  strong	  correlation	  between	  the	  identity	  of	  the	  halogen	   atom	   on	   the	   phenyl	   ring	   and	   the	   effectiveness	   of	   the	   compound.	   	   Iodine	  imparted	   the	   best	   inhibitory	   activity,	   followed	   by	   bromine,	   chlorine	   (data	   not	  
shown)	  and	  fluorine,	  in	  that	  order	  (entries	  2	  and	  3,	  4	  and	  8,	  and	  5	  and	  6).	  	  The	  pattern	  of	   halo-­‐substitution	   on	   the	   phenyl	   ring	   was	   also	   evaluated.	   	   Since	   the	  meta-­‐iodo	  isomer	  did	  not	  exhibit	  any	  effect	  over	  its	  para	  analog	  (entries	  8	  and	  10),	  we	  pursued	  the	   latter	  due	   to	   its	  simpler	  purification	  process.	   	  Lastly,	  a	   fluorinated	  substituent,	  the	   trifluoromethoxy	   group,	   did	   not	   alter	   the	   potency	   of	   the	   compound	   when	  compared	  to	  the	  parental	  bromo	  substitution	  (entries	  4	  and	  9).	  	  Another	  part	  of	  the	  molecule	   that	  was	   subject	  of	   analysis	  was	   the	  alkyl	   ether	  moiety	  on	   the	  quinoline	  ring.	   	   The	   replacement	   of	   the	   ethyl	   group	   by	   either	   a	   methyl	   or	   isopropyl	  counterpart	  resulted	  in	  a	  slight	  decrease	  in	  inhibitory	  activity	  (entries	  1	  and	  2,	  and	  4,	  
6	  and	  7).	   	   Of	   all	   analogs	   tested,	   TDRL-­‐551	   (entry	  8)	   exhibited	   the	   highest	   in	   vitro	  potency,	  as	  well	  as	  cellular	  efficacy.	  	  	  To	   interrogate	   the	  most	  potent	  compound	  TDRL-­‐551	  we	  directly	  compared	  its	  activity	  of	  its	  predecessor	  TDRL-­‐505.	  	  The	  data	  presented	  in	  Figure	  11A	  compare	  the	  EMSA	  based	  in	  vitro	  inhibitory	  activity	  of	  TDRL-­‐551	  with	  that	  of	  TDRL-­‐505.	  	  The	  IC50	   values,	   calculated	   form	   the	  plotted	  graphs	   (Figure	  11B),	  were	   found	   to	  be	  18	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and	   38	   μM,	   respectively,	   making	   TDRL-­‐551	   greater	   than	   twice	   as	   potent	   than	   its	  predecessor.	  	  	  
	  
Figure	   11:	   In	  vitro	   analysis	   of	   TDRL-­‐551	   inhibitory	   activity	   for	   RPA.	  A)	  RPA	  was	  incubated	  with	  compounds	  TDRL-­‐505	  and	  TDRL-­‐551	  ranging	  from	  1-­‐125	  μM.	  	  DNA	  binding	  was	  analyzed	  by	  EMSA	  as	  described	  in	  Methods.	   	  The	  position	  of	  free	  DNA	  and	  the	  DNA–RPA	  complex	  is	  denoted	  in	  the	  figure.	  	  The	  *	  indicated	  the	  position	  of	  the	  E.	   	   coli	   SSB-­‐DNA	  complex.	   	  B)	  Quantification	  of	   the	  data	  presented	   in	  panel	  A.	  	  Data	   represent	   the	   average	   and	   SD	   of	   three	   independent	   determinations	   and	   the	  data	   were	   fitted	   using	   non-­‐linear	   regression	   analysis	   (Sigmaplot)	   to	   obtain	   IC50	  values.	  	   The	   two	  potential	  mechanisms	   for	   inhibition	  are	   either	   a	  direct	   interaction	  with	  the	  protein	  or	  an	  interaction	  with	  the	  DNA	  that	  renders	  it	  unable	  to	  bind	  to	  the	  protein.	   	   While	   our	   previous	   results	   suggested	   that	   the	   505	   class	   of	   compounds	  inhibits	   DNA	   binding	   activity	   via	   a	   direct	   interaction	   with	   the	   protein	   RPA,	   we	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sought	   to	   determine	   if	   TDRL-­‐551	   employed	   the	   same	   mechanism.	   	   We	   therefore	  assessed	   the	   ability	   of	   TDRL-­‐551	   to	   bind	   to	   DNA	   directly	   using	   a	   fluorescence	  displacement	  assay.	   	  The	  results	  presented	   in	  Figure	  12	  demonstrate	   that	  no	  DNA	  binding	   activity	   was	   observed.	   	   These	   data	   support	   our	   hypothesis	   that	   the	  compound	   inhibits	   the	   protein-­‐DNA	   interaction	   by	   binding	   directly	   to	   the	   RPA	  protein	  and	  not	  via	  binding	  to	  the	  DNA.	  
	  
Figure	   12:	   Fluorescent	  displacement	   assay.	   	  Assays	  were	  performed	  as	  described	  and	   the	   indicated	   concentration	  of	   551	  or	   doxorubicin	  was	   titrated	   into	   reactions	  containing	  DNA	  and	  SybrGreen.	  	  The	  fluorescence	  was	  measured	  and	  data	  represent	  the	  average	  and	  SD	  of	  three	  independent	  determinations.	  	  
 To	   further	   delve	   into	   the	  mechanism	  of	   binding,	  we	   tested	  whether	   TDRL-­‐551	  could	  inhibit	  RPA	  DBD-­‐A/B	  binding	  (the	  major	  high	  affinity	  DNA	  binding	  core)	  to	  DNA.	  Both	  TDRL-­‐551	  and	  TDRL-­‐505	   inhibit	  RPA	  DBD-­‐A/B-­‐DNA	   interaction	  and	  hence	  employ	  a	  similar	  inhibition	  mechanism	  (Figure	  13).	  Interestingly,	  we	  did	  not	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observe	   a	   significant	   difference	   in	   the	   inhibition	   potency	   of	   TDRL-­‐505	   and	  TDRL-­‐551	   for	   RPA	   DBD-­‐A/B.	  We	   speculate	   the	   improved	   potency	   of	   TDRL-­‐551	   for	   full	  length	  RPA	   could	   be	   due	   to	   its	   binding	   at	   other	   sites	   in	  RPA	   and	   thus	   the	   overall	  potency	  of	  the	  molecule	  could	  be	  a	  result	  of	  multiple	  binding	  sites.	  
Figure	  13:	   In	  vitro	  analysis	  of	  TDRL-­‐551	  inhibitory	  activity	  for	  RPA-­‐A/B	  Box.	  RPA-­‐A/B	  Box	  was	  incubated	  with	  compounds	  TDRL-­‐505	  and	  TDRL-­‐551	  ranging	  from	  25-­‐100	  μM.	  	  DNA	  binding	  was	  analyzed	  by	  EMSA	  as	  described	  in	  Methods.	  	  The	  position	  of	  free	  DNA	  and	  the	  DNA–RPA	  A/B	  complex	  is	  denoted	  in	  the	  figure.	  	  	  	   3.4. Cellular	  activity	  of	  TDRL-­‐551	  3.4.1. Single	  agent	  anti-­‐cancer	  activity	  of	  RPA	  inhibitors	  in	  EOC	  cell	  line	  Considering	   the	   essential	   role	   of	   RPA	   in	   S-­‐phase	   DNA	   replication	   (62)	   and	  our	  previous	  data	  with	  both	  reversible	  and	   irreversible	  RPA	   inhibitors	   (55,56,58),	  we	   evaluated	   the	   TDRL-­‐505	   analogs	   for	   single	   agent	   anti-­‐cancer	   activity	   in	   the	  A2780	  EOC	  cell	  line	  using	  clonogenic	  survival	  assays	  (Table	  1).	  	  Consistent	  with	  our	  
in	   vitro	   EMSA	   based	   studies,	   TDRL-­‐551	   showed	   the	   best	   single	   agent	   activity	   in	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these	  cells.	   	  Also	  in	  line	  with	  the	  in	  vitro	  results	  was	  the	  relative	  cellular	  inhibitory	  activity	   of	   all	   tested	   compounds.	   	   Figure	   14	   shows	   the	   data	   obtained	   from	  clonogenic	  survival	  assays,	  comparing	  the	  single	  agent	  activity	  of	  our	  original	   lead	  TDRL-­‐505	  and	  our	  optimized	  lead,	  TDRL-­‐551.	  	  TDRL-­‐505’s	  IC50	  was	  found	  to	  be	  55	  μM,	  while	  TDRL-­‐551	  was	  twice	  as	  potent	  with	  an	  IC50	  of	  25	  μM.	   	   Interestingly,	   the	  degree	   of	   improvement	   in	   potency	   remained	   consistent	   between	   the	   in	   vitro	   and	  cellular	  assays.	  	  	  
	  
Figure	  14:	  Cellular	  activity	  of	  TDRL-­‐505	  and	  TDRL-­‐551	  in	  A2780.	  A2780	  cells	  were	  treated	  with	  RPA	   inhibitor	  TDRL-­‐505	  or	  TDRL-­‐551	   for	  48	  hours	  and	  viability	  was	  assessed	   in	  a	  colony	   formation	  assay	  as	  described	   in	  Methods.	   	  The	  colonies	  were	  counted	   and	   normalized	   to	   the	   untreated	   controls	   to	   determine	   cellular	   viability.	  	  The	   data	   represent	   the	   average	   and	   SEM	   from	   three	   independent	   determinations	  and	   the	  data	  were	   fit	  using	  non-­‐linear	  regression	  analysis	   (Sigmaplot)	   to	  calculate	  cellular	  IC50s.	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To	   ensure	   that	   the	   activity	  was	   not	   cell	   line	   specific,	   we	   also	   assessed	   the	  single	  agent	  activity	  of	  TDRL-­‐551	  in	  three	  other	  EOC	  cell	  lines,	  SKOV3	  and	  OVCA429	  (ATCC)	   both	   of	   which	  were	   isolated	   from	   patients	   with	   recurrent	   ovarian	   cancer	  following	  platinum	   therapy	  and	   the	   cisplatin	   resistant	  A2780	  derivative	   (63).	   	  We	  also	  assessed	  activity	  in	  the	  H460	  NSCLC	  cell	  line.	  	  In	  each	  case,	  TDRL-­‐551	  displayed	  single	  agent	  activity	  similar	  to	  that	  observed	  in	  the	  parental	  A2780	  EOC	  cells	  (Figure	  15)	   demonstrating	   that,	   as	   would	   be	   expected	   for	   an	   RPA	   inhibitor,	   the	  mode	   of	  activity	  is	  not	  restricted	  to	  a	  single	  cell	  line	  or	  cancer	  type.     
	  
Figure	   15:	   Analysis	   of	   TDRL551	   single	   agent	   activity	   in	   H460	   NSCLC,	   SKOV3,	  A2780/R	   and	   OVCA429	   EOC	   cells.	   A2780	   cells	   were	   treated	   with	   RPA	   inhibitor	  TDRL-­‐505	   or	   TDRL-­‐551	   for	   48	   hours	   and	   viability	   was	   assessed	   in	   a	   colony	  formation	   assay	   as	   described	   in	   Methods.	   	   The	   colonies	   were	   counted	   and	  normalized	   to	   the	   untreated	   controls	   to	   determine	   cellular	   viability.	   	   The	   data	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represent	   the	   average	   and	   SEM	   from	   three	   independent	   determinations	   and	   the	  data	  were	   fit	  using	  non-­‐linear	   regression	  analysis	   (Sigmaplot)	   to	   calculate	   cellular	  IC50s.	  	   3.4.2. Synergy	  with	  DNA	  damaging	  chemotherapeutic	  agents	  in	  EOC	  Since	   repair	   and	   tolerance	   of	   Pt-­‐DNA	   lesions	   predominantly	   occur	   via	  NER	  and	  HR,	  cellular	  inhibition	  of	  RPA	  should	  have	  a	  dramatic	  effect	  on	  the	  sensitization	  of	  cancer	  cells	   to	  Pt.	   	   In	  order	  to	  determine	  whether	   inhibition	  of	  RPA	  with	  TDRL-­‐551	  synergizes	  with	  Pt	   in	  EOC	  cells,	  we	  performed	  combination	   treatment	  studies	  with	  TDRL-­‐551	  and	  cisplatin.	  	  We	  used	  the	  platinum	  sensitive	  A2780	  cell	  line	  as	  our	  cell	   culture	   model	   for	   EOC.	   	   Figure	   16	   shows	   the	   dose-­‐response	   curves	   for	   the	  combination	  treatment	  of	  TDRL-­‐551	  and	  cisplatin	  along	  with	  the	  appropriate	  single	  agent	   controls	   from	   a	   representative	   experiment.	   An	   average	   of	   three	   biological	  replicate	   experiments	   for	   combination	   studies	   of	   TDRL-­‐551	  with	   Pt	   in	  A2780	   cell	  line	  was	  performed	  to	  determine	  the	  combination	  index	  (Figure	  18).	  	  Our	  data	  show	  a	   synergistic	   effect	   indicated	  by	  a	  CI	  <	  1	  at	  0.5	  or	  higher	   fraction	  of	   cells	   affected.	  	  The	   data	   obtained	   are	   consistent	   with	   our	   hypothesis	   that	   RPA	   inhibition	  makes	  cancer	  cells	  more	  sensitive	  towards	  Pt	  and	  hence	  acts	  synergistically	  with	  cisplatin	  treatment.	  	  	  Since	  RPA	  also	  plays	  a	  crucial	  role	  in	  replication,	  we	  also	  tested	  TDRL-­‐551	  in	  combination	  with	  etoposide,	  a	  topoisomerase	  II	   inhibitor.	   	  Figure	  17	  demonstrates	  the	  dose-­‐response	  curves	  for	  the	  combination	  treatment	  of	  TDRL-­‐551	  and	  etoposide	  along	  with	  the	  appropriate	  single	  agent	  controls	  from	  a	  representative	  experiment.	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An	   average	   of	   three	   biological	   replicate	   experiments	   for	   combination	   studies	   of	  TDRL-­‐551	   with	   etoposide	   in	   A2780	   cell	   line	   was	   performed	   to	   determine	   the	  combination	  index.	  TDRL-­‐551	  was	  mildly	  synergistic	  with	  etoposide	  at	  the	  highest	  fraction	  of	  cells	  affected	  (>	  0.8)	  (Figure	  18).	  
	  
Figure	   16:	   Dose-­‐response	   curves	   for	   TDRL-­‐551	   and	   Pt.	   Cell	   viability	   was	  determined	   from	   clonogenic	   survival	   assays	   for	   TDRL-­‐551	   and	   Pt	   combination	  treatment	   along	  with	   single	   agent	   controls	   in	   A2780	   cell	   line	   as	   described	   in	   the	  Methods.	  Constant	  Ratio	  of	  1	  equals	  40	  μM	  for	  TDRL-­‐551	  and	  1.5	  μM	  for	  Pt.	  The	  data	  is	   from	   a	   representative	   experiment	   from	   a	   set	   of	   three	   independent	   biological	  replicates.	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Figure	   17:	   Dose-­‐response	   curves	   for	   TDRL-­‐551	   and	   etoposide.	   Cell	   viability	   was	  determined	   from	   clonogenic	   survival	   assays	   for	   TDRL-­‐551	   and	   etoposide	  combination	   treatment	   along	   with	   single	   agent	   controls	   in	   A2780	   cell	   line	   as	  described	   in	   the	  Methods.	  Constant	  Ratio	  of	  1	  equals	  60	  μM	   for	  TDRL-­‐551	  and	  75	  nM	  for	  etoposide.	  The	  data	  is	  from	  a	  representative	  experiment	  from	  a	  set	  of	  three	  independent	  biological	  replicates.	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Figure	  18:	  The	  CI	  of	  TDRL-­‐551	  with	  Pt	  and	  etoposide.	  CIs	  were	  determined	  through	  a	  Chou-­‐Talalay	  based	  approach	  as	  described	  in	  the	  Methods.	  	  The	  data	  represent	  the	  average	  and	  SEM	  from	  three	  independent	  determinations.	  	   3.5. RPA	   Inhibitor	   TDRL-­‐551	   displays	   single	   agent	   anti-­‐cancer	   activity	   and	  sensitizes	  NSCLC	  tumors	  to	  platinum	  based	  treatment	  in	  vivo.	  To	  determine	  the	  effect	  of	  RPA	  inhibition	  via	  TDRL-­‐551	  treatment	  in	  vivo	  we	  first	  assessed	  tolerability	  and	  experiments	  demonstrated	  no	  body-­‐weight	  loss	  with	  intraperitoneal	   administration	  up	   to	  200	  mg/kg	   (Figure	  19).	   	   A	   slight	   decrease	   in	  body	  weight	  was	   observed	   at	   300	  mg/kg,	   but	  was	  not	   statistically	   significant.	   Co-­‐treatment	  with	  carboplatin	  was	  also	  assessed	  and	  again,	  no	  adverse	  effects	  or	  loss	  of	  weight	  was	  observed	  up	  to	  200	  mg/kg	  (data	  not	  shown).	  	  We	  then	  determined	  anti-­‐cancer	  activity	  in	  H460	  NSCLC	  xenografts.	  	  Initial	  pharmacokinetic	  analysis	  revealed	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that	  ability	   to	  achieve	  a	  plasma	  concentration	  of	  >20	  μM	  with	  a	  half-­‐life	  of	  over	  7	  hours	  (data	  not	  shown).	  	  	   	  
Figure	  19: Overall	  change	  in	  body-­‐weight	  in	  response	  to	  treatment	  with	  TDRL-­‐551.	  Tolerability	   of	   TDRL-­‐551	  was	   assessed	   via	   body	  weight	   determinations	   following	  triweekly	  dosing	  at	  the	  indicated	  drug	  concentrations.	  	  Mice	  were	  treated	  on	  days	  1,	  3,	  5,	  8,	  10,	  and	  12	  IP	  as	  described	  in	  Methods.	   	  Data	  are	  reported	  as	  the	  percent	  of	  body	  weight	  on	  day	  1	  and	  represent	  the	  mean	  ±	  standard	  error	  of	  the	  mean	  (n=3).	  There	  was	  no	  statistically	  significant	  difference	  between	  each	  of	  the	  treatment	  arms	  compared	  to	  vehicle	  control	  as	  determined	  by	  student’s	  t	  test	  described	  in	  methods.	  	   Tumor	   cells	   were	   therefore	   implanted	   in	   NOD/SCID	   mice	   that	   were	  randomized	  and	  treated	  with	  vehicle,	  TDRL-­‐551;	  carboplatin;	  or	  the	  combination	  of	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TDRL-­‐551	  and	  carboplatin	  (Figure	  20).	  	  Carboplatin	  is	  often	  used	  in	  the	  treatment	  of	  NSCLC	  and	  forms	  DNA	  adducts	  chemically	  indistinguishable	  from	  those	  forms	  with	  cisplatin.	   	   As	   a	   result	   of	   the	   similarity	   in	   the	   DNA	   adducts	   formed	   between	  carboplatin	  and	  cisplatin,	   the	  repair	  pathways	  that	   impact	  sensitivity	  are	   identical.	  	  Tumor	   volumes	   were	   monitored	   for	   2	   weeks	   following	   initiation	   of	   treatment	  regimens	  and	  averages	  for	  each	  treatment	  arm	  are	  reported.	  	  Each	  of	  the	  treatment	  arms	  is	  clearly	  distinct	  from	  the	  untreated	  control	  group.	  The	  tumor	  volumes	  for	  all	  treatment	   arms	   at	   all	   data	   points	   post	   day	   8	  were	   statistically	   different	   from	   the	  tumor	  volumes	  for	  the	  corresponding	  data	  points	  in	  the	  vehicle	  control,	  apart	  from	  carboplatin	   treatment	  on	  day	  14.	   	  Carboplatin	   treatment	  and	  TDRL-­‐551	  displayed	  similar	  growth	  inhibition	  of	  tumors.	  	  There	  was	  no	  statistically	  significant	  difference	  at	   any	   of	   the	   data	   points	   between	   carboplatin	   and	   TDRL-­‐551	   treatment.	   This	  demonstrates	  single	  agent	  anti-­‐cancer	  activity	  of	  TDRL-­‐551	  in	  vivo	  that	  is	  consistent	  with	   the	   cellular	   assays	   reported	   above.	   	   Interestingly,	  mice	   receiving	   carboplatin	  and	  TDRL-­‐551	  demonstrated	  the	  slowest	  tumor	  growth,	  consistent	  with	  TDRL-­‐551	  sensitizing	   cells	   to	   platinum.	   The	   difference	   in	   the	   tumor	   volumes	   between	   the	  combination	  treatment	  and	  TDRL-­‐551	  alone	  was	  statistically	  significant	  at	  all	  data	  points	   post	   day	   14.	   However,	   the	   tumor	   volumes	   for	   carboplatin	   and	   the	  combination	   treatment	  were	  statistically	  different	  only	  at	  day	  17.	  The	  variation	   in	  the	   initial	   tumor	   volumes	   (range	   =	   120.5	   mm3)	   may	   partially	   explain	   the	   huge	  variation	  in	  the	  tumor	  volumes	  at	  day	  20	  and	  21	  and	  hence	  the	  statistics.	  These	  data	  demonstrate	   single	   agent	   activity	   for	   TDRL-­‐551	   in	   vivo	   in	   NSCLC	   tumors	   and	   a	  potential	  to	  sensitize	  these	  tumors	  to	  Pt-­‐based	  therapy.	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4. DISCUSSION	  	   The	   research	   presented	   in	   this	   thesis	   describes	   the	   synthesis,	   structure	  activity	   relationships	   and	   in	   vitro	   and	   cellular	   activity	   of	   novel	   reversible	   RPA	  inhibitors	  in	  EOC	  and	  NSCLC	  (Figures	  7-­‐15;	  Table	  1).	   	  We	  have	  demonstrated	  both	  single	   agent	   activity	   and	   synergy	   in	   combination	   with	   DNA	   damaging	  chemotherapeutic	   agents;	   cisplatin	   and	   etoposide	   (Figures	   16-­‐18).	   	   In	   vivo	   data	  demonstrate	   good	   tolerability	   and	   potential	   therapeutic	   efficacy	   in	   combination	  with	  carboplatin	  in	  a	  NSCLC	  xenograft	  model	  (Figures	  19-­‐20).	   	  This	  represents	  the	  first	   in	   vivo	   deployment	   of	   a	   small	   molecule	   inhibitor	   targeting	   the	   RPA-­‐DNA	  interaction.	   	   The	   SARs	   defined	   the	   necessary	   substituents	   for	   activity	   while	  maintaining	  excellent	  bioavailability	  (data	  not	  shown).	  	  These	  data	  demonstrate	  that	  to	   achieve	   in	  vivo	   activity	   a	   balance	   between	   potency	   and	   bioavailability	   can	   lean	  towards	   lower	   affinity	   as	   long	   as	   PK	   parameters	   allow	   clinically	   effective	  concentrations	  to	  be	  maintained.	   	  This	  balance	   is	  especially	   important	   in	   targeting	  RPA	  an	  essential	  protein	  with	  homozygous	  mutations	  being	  embryonically	  lethal	  in	  mice,	  while	  heterozygous	  mutants	  having	  an	  early	  predisposition	  to	  cancer	  (64).	  	  No	  loss	   of	   function	   mutation	   for	   RPA	   has	   been	   reported	   in	   humans	   and	   genetic	  knockdown	  of	  RPA	  affects	  cellular	  viability	  (62).	  	  Consequently,	  targeting	  RPA	  could	  have	   potential	   negative	   effects	   on	   rapidly	   dividing	   healthy	   cells,	   such	   as	   gut	  epithelial,	  hematopoietic,	  or	  hair	  follicle,	  and	  it	  could	  lead	  to	  unwanted	  side	  effects.	  	  For	   this	   reason,	   exploiting	   the	   separation	   of	   function	   phenomena	   in	   RPA	   in	   a	  manner	   amenable	   for	   therapeutic	   intervention	   is	   crucial.	   	   Our	   laboratory	   has	  previously	   published	   minimal	   cytotoxic	   effects	   on	   peripheral	   blood	   lymphocytes	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with	  the	  TDRL-­‐505	  inhibitor	  (58).	  	  Moreover,	  our	  mouse	  toxicity	  studies	  with	  TDRL-­‐551	  indicate	  no	  significant	  overall	  change	  in	  body	  weight	  for	  doses	  up	  to	  300	  mg/kg,	  but	  show	  anti-­‐tumor	  activity	  at	   the	  same	  dosage	   in	  a	   lung	  cancer	  xenograft	  model	  (Figures	   19-­‐20).	   	   We	   hypothesize	   that	   since	   cancer	   cells	   are	   undergoing	   an	  abnormal	  unregulated	  rate	  of	  proliferation,	   they	  are	   in	  a	  state	  of	  replicative	  stress	  and	  their	  dependence	  on	  RPA	  can	  be	  used	  to	  obtain	  a	  therapeutic	  window	  without	  harming	  the	  normal	  cells.	   	  This	  can	  also	  be	  understood	  by	  analogy	  to	  an	  oncogene	  addiction	  model,	   in	  which	  cancer	  cells	  have	  a	  higher	  dependence	  on	   the	  oncogene	  compared	   to	   normal	   cells	   and	   hence	   can	   be	   selectively	   targeted.	   	   Finally,	   RPA’s	  overexpression	   has	   been	   correlated	   with	   multiple	   cancers	   like	   breast,	   lung	   and	  colon,	  and	  it	  has	  also	  been	  associated	  with	  metastasis	  (65-­‐68).	  	  Thus,	  clinical	  reports	  of	   altered	   RPA	   expression	   in	   a	   variety	   of	   cancers	   make	   RPA	   a	   promising	   novel	  therapeutic	  target.	  It	  is	  also	  important	  to	  elucidate	  whether	  our	  inhibitors	  exclusively	  impair	  the	  repair	  function	  of	  RPA	  without	  compromising	  its	  role	  in	  replication.	  	  Our	  previously	  published	  data	  with	  inhibitor	  TDRL-­‐505	  demonstrate	  a	  G1	  cell	  cycle	  arrest,	  however	  the	  cells	   those	  are	  already	   in	  S-­‐phase	  progress	  through	  the	  replication	  phase	  (58).	  	  This	  indicates	  that	  our	  inhibitors	  are	  either	  blocking	  the	  initial	  phase	  of	  replication	  initiation	  or	  early	  origin	   firing	  and	   inhibiting	  the	  transition	   from	  G1	  to	  S	  phase,	  or	  causing	  an	  alteration	   in	   the	  DNA	  damage	  checkpoint	   signaling.	   	   In	  either	   case,	   the	  505	   class	   of	   inhibitors	   do	   not	   block	   progression	   through	   S-­‐phase	   once	   the	   G1-­‐S	  transition	   has	   occurred.	   	   Our	   current	   results	   demonstrating	   synergy	   of	   TDRL-­‐551	  with	   Pt	   in	   an	   EOC	   cell	   line	   (Figure	   18),	   along	   with	   our	   published	   data	   showing	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synergy	  of	  TDRL-­‐505	  with	  Pt	   in	  a	   lung	  cancer	  cell	   line	  (58)	   indicates	  that	  our	  RPA	  inhibitors	   are	   impairing	   the	   repair	   function	   of	   RPA.	   	   The	   major	   limitation	   for	  successful	   treatment	  of	  a	  variety	  of	  cancers,	   including	  EOC,	  has	  been	  the	  tolerance	  and	   repair	   of	   Pt-­‐DNA	   adducts	   and	   has	   been	   specifically	   correlated	   to	   increased	  repair	  in	  a	  variety	  of	  ovarian	  cancer	  cell	  lines	  (69).	  	  Hence,	  inhibiting	  DNA	  repair	  by	  targeting	  RPA	  could	  have	  a	  major	  significance	  for	  cancer	  therapy.	  We	   also	   examined	   the	   ability	   of	   TDRL-­‐551	   to	   synergize	   with	   etoposide,	   a	  topoisomerase	   II	   inhibitor	   (Figures	   17-­‐18).	   	   Etoposide	   treatment	   leads	   to	   both	  single	  and	  double	  stranded	  DNA	  breaks	  as	  well	  as	  stalling	  and	  collapse	  of	  replication	  forks	   (70,71).	   	   Inhibiting	   RPA’s	   replication	   function	   could	   further	   enhance	   the	  number	   of	   DNA	   breaks	   produced	   on	   etoposide	   treatment	   and	   improve	   the	  effectiveness	  of	   the	   treatment.	   	  Although	  TDRL-­‐505	  has	  been	  previously	  shown	   to	  be	  highly	  synergistic	  with	  etoposide	   in	   lung	  cancer	  cells	   through	  a	   flow	  cytometry	  based	   Annexin-­‐PI	   staining	   assay	   (58),	   its	   optimized	   analog,	   TDRL-­‐551,	   showed	  modest	   synergy	  with	   etoposide	   at	   the	  highest	   fractions	   of	   cells	   affected	   (>	  0.8)	   in	  A2780	  EOC	  cell	  line	  through	  colony	  formation	  assay	  (Figure	  18).	  	  Compound	  TDRL-­‐551	   may	   be	   more	   specific	   in	   targeting	   the	   repair	   function	   of	   RPA	   than	   its	  predecessor	  TDRL-­‐505	  and	  hence	  doesn’t	  significantly	   impact	  replication	  and	  only	  mildly	  synergizes	  with	  etoposide.	  	  Alternatively,	  the	  differences	  may	  be	  a	  function	  of	  the	   cell	   lines	   used	   and	   cancer	   types	   being	   investigated.	   	   While	   cisplatin	   and	  etoposide	  are	  the	  standard	  drugs	  used	  in	  treatment	  against	  lung	  cancer,	  the	  therapy	  for	  ovarian	  cancer	  involves	  the	  combination	  of	  platinum	  and	  taxol.	  	  Etoposide	  is	  not	  a	   first	   line	   therapy	   for	   EOC	   and	   hence	   improving	   its	   effectiveness	  may	   be	   limited	  
	   47	  
based	  on	  the	  cancer.	  	  Lastly,	  we	  cannot	  rule	  out	  that	  the	  differing	  synergy	  outcomes	  are	   a	   consequence	   of	   the	   type	   of	   assay	   performed	   in	   each	   case.	   	   Despite	   these	  caveats,	  the	  important	  finding	  is	  that	  RPA	  inhibition	  with	  TDRL-­‐551	  synergizes	  with	  cisplatin	   in	  EOC	  and	  may	  provide	  an	  avenue	   to	   increase	   sensitivity	   to	  platinum	   in	  the	  clinic.	  	   RPA	  inhibitors	  can	  be	  used	  as	  DNA	  repair	  inhibitors	  to	  overcome	  resistance	  to	  platinum	  based	  chemotherapies.	  	  Inhibiting	  DNA	  repair	  with	  SMIs	  can	  be	  used	  in	  combination	  with	  Pt	  both	  at	  first	  line	  and	  second	  line	  stage	  of	  therapy	  (Figure	  21).	  	  In	  first	  line	  therapy,	  Pt	  in	  combination	  with	  RPA	  inhibitors	  could	  lead	  to	  maximum	  effectiveness	  by	  killing	  the	  majority	  of	  cancer	  cells,	  which	  are	  now	  sensitized	  to	  Pt	  due	   to	   inhibition	   of	   DNA	   repair.	   	   This	   may	   certainly	   still	   lead	   to	   some	   surviving	  cancer	   cells	   that	   are	   resistant	   to	   the	   treatment	   due	   to	   other	  mechanisms,	   such	   as	  reduced	   uptake	   of	   platinum,	   increased	   drug	   efflux,	   or	   increased	   expression	   of	  proteins	   like	   glutathione	   that	   bind	   and	   inactivate	   Pt	   in	   the	   cells.	   	   However,	   since	  there	  will	  be	  less	  number	  of	  surviving	  cancer	  cells	  to	  relapse	  with	  platinum	  resistant	  forms,	   any	   increase	   in	   the	   effectiveness	   of	   the	   first	   line	   therapy	  would	   lead	   to	   an	  improved	   PFS,	   which	   can	   be	   clinically	   significant.	   	   As	   second	   line	   therapy,	   RPA	  inhibitors	  can	  be	  used	  in	  combination	  with	  Pt	  to	  re-­‐sensitize	  the	  platinum	  resistant	  cancers,	  also	  leading	  to	  an	  increase	  in	  PFS.	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mass	  spectroscopy	  technique	  could	  be	  used	  to	  determine	  Pt	  repair	  kinetics	  in	  cells	  with	  and	  without	  treatment	  with	  RPA	  inhibitors.	  This	  would	  help	  in	  deciphering	  the	  mechanism	  of	  Pt-­‐sensitization	  observed	  in	  response	  to	  these	  inhibitors.	  In	  vitro	  NER	  assays	  could	  be	  performed	  to	  determine	  whether	  TDRL-­‐551	  class	  of	  RPA	  inhibitors	  directly	   inhibit	  NER.	   Impact	  of	  RPA	   inhibitors	  on	  cellular	  NER	  activity	   can	  also	  be	  determined	   by	   the	   new	   technique	   established	   by	   Dr.	   Sancar	   and	   group	   which	  measures	  the	  amount	  of	  excised	  oligonucleotides	  following	  NER	  (72).	  These	  assays	  will	   provide	   confirmatory	   evidence	   for	   the	   inhibition	   of	   NER	   by	   RPA	   inhibitors.	  Similarly,	  whether	  inhibition	  of	  RPA	  by	  small	  molecule	  inhibitors	  inhibits	  HR	  can	  be	  determined	  by	  commercially	  available	  HR	  assay	  kits.	  Moreover,	  Pt-­‐sensitization	  and	  the	   synergistic	   impact	   of	   RPA	   inhibitors	   should	   be	  measured	   as	   a	   function	   of	   HR	  status.	  This	  would	  help	  determine	  the	  efficacy	  of	  these	  inhibitors	  in	  a	  large	  subset	  of	  ovarian	  cancers	  which	  are	  HR	  deficient.	  A	  BRCA1	  knockdown	  A2780	  cell	  line	  would	  be	  a	  great	  approach	  to	  complement	  our	  current	  data	  to	  answer	  the	  above	  question.	  Other	   BRCA1/2	   deficient	   cell	   culture	   models	   along	   with	   their	   complemented	   wt	  counterparts	   can	   be	   used	   to	   validate	   the	   result	   in	  multiple	   cell	   lines.	   Finally,	   SAR	  studies	   can	   be	   pursued	   to	   obtain	  more	   potent	   and	   specific	   inhibitors	   and	   further	  optimize	   the	   solubility	   and	   bioavailabilty	   parameters	   of	   the	   current	   inhibitors.	  These	   studies	   will	   provide	   a	   strong	   base	   for	   the	   development	   of	   small	   molecule	  inhibitors	   targeting	   RPA-­‐DNA	   interaction	   to	   overcome	   Pt-­‐resistance	   at	   a	   clinical	  scale.	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